Risk factors for critical disease and death from hand, foot and mouth disease

Pediatric Infectious Disease Journal

Volumn 33, Issue 9, 2014, Pages 966-970

  He, Yilin ^a,b   Yang, Jianguo ^a   Zeng, Guang ^b   Shen, Tao ^b   Fontaine, Robert E ^c   Zhang, Lijie ^b   Shi, Guoqing ^b   Wang, Yulin ^d   Li, Qin ^d   Long, Jiang ^d  

^a Taizhou Center for Disease Control and Prevention   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Chongqing Center for Disease Control and Prevention   (China)

Author keywords

Death; Foot and mouth disease; Hand; Risk factors; Treatment

Indexed keywords

ANDROGRAPHOLIDE; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; GLUCOCORTICOID; ANTIVIRUS AGENT; DITERPENE;

ARTICLE; CHILD; CHINESE MEDICINE; CONTROLLED STUDY; COXSACKIE VIRUS A; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; CASE CONTROL STUDY; CHINA; CRITICAL ILLNESS; EPIDEMIOLOGY; HAND, FOOT AND MOUTH DISEASE; MORTALITY; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; TIME;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHINA; CRITICAL ILLNESS; DITERPENES; FEMALE; GLUCOCORTICOIDS; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFANT; MALE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84926148671     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000319     Document Type: Article

References (34)

1. Hamaguchi T, Fujisawa H, Sakai K, et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis. 2008;14:828-830.
2. Tseng FC, Huang HC, Chi CY, et al.; CDC-Taiwan Virology Reference Laboratories and Sentinel Physician Network. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol. 2007;79:1850-1860.
3. Wang Y, Feng Z, Yang Y, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22:781-792.
4. Shimizu H, Utama A, Onnimala N, et al. Molecular epidemiology of enterovirus 71 infection in the Western Pacific Region. Pediatr Int. 2004;46:231-235.
5. Bible JM, Pantelidis P, Chan PK, et al. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17:371-379.
6. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91-107.
7. Suzuki Y, Taya K, Nakashima K, et al. Risk factors for severe hand foot and mouth disease. Pediatr Int. 2010;52:203-207.
8. Yang T, Xu G, Dong H, et al. A case-control study of risk factors for severe hand-foot-mouth disease among children in Ningbo, China, 2010-2011. Eur J Pediatr. 2012;171:1359-1364.
9. Ma H, He F, Wang J, et al. Glucocorticoid and pyrazolone treatment of acute fever is a risk factor for critical and life-threatening Human Enterovirus 71 infection during an outbreak in China, 2008. Pediatr Infect Dis J. 2010;29:1-6.
10. Chong CY, Chan K P, Shah VA, et al. Hand, foot and mouth disease in Singapore: a comparison of fatal and non-fatal cases. Acta Paediatr. 2003;92:1163-1169.
11. Weng TY, Chen LC, Shyu H W, et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005;67:31-37.
12. Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197:854-857.
13. Sim AC, Luhur A, Tan TM, et al. RNA interference against enterovirus 71 infection. Virology. 2005;341:72-79.
14. Liu ML, Lee Y P, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86(pt 12):3263-3269.
15. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326-333.
16. Chinese Ministry of Public Health (revised in 2010). Available at: http://www.moh.gov. cn/publicfiles/business/htmlfiles/mohyzs/s3586/201004/46884. Accessed 10, January 2012.
17. Tong CY, Bible JM. Global epidemiology of enterovirus 71. Future Virol. 2009;4:501-510.
18. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996;272:50-53.
19. Lin Y W, Chang KC, Kao CM, et al. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol. 2009;83:6477-6483.
20. Lei X, Sun Z, Liu X, et al. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J Virol. 2011;85:8811-8818.
21. Liu ML, Lee Y P, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86(pt 12):3263-3269.
22. Yang KD, Yang MY, Li CC, et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis. 2001;183:850-856.
23. Schimmer B P, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs, inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006;59.
24. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954-963.
25. Frey FJ, Speck RF. [Glucocorticoids and infection]. Schweiz Med Wochenschr. 1992;122:137-146.
26. Rao YK, Damu AG, Rao AJ, et al. Flavonoids from andrographis viscosula. Chem Pharm Bull (Tokyo). 2003;51:1374-1376.
27. Akowuah GA, Zhari I, Mariam A, et al. Absorption of andrographolides from Andrographis paniculata and its effect on CCl (4)-induced oxidative stress in rats. Food Chem Toxicol. 2009;47:2321-2326.
28. Sheeja K, Shihab PK, Kuttan G. Antioxidant and anti-inflammatory activities of the plant Andrographis paniculata Nees. Immunopharmacol Immunotoxicol. 2006;28:129-140.
29. Wiart C, Kumar K, Yusof MY, et al. Antiviral properties of ent-labdene diterpenes of Andrographis paniculata nees, inhibitors of herpes simplex virus type 1. Phytother Res. 2005;19:1069-1070.
30. Rahman NNNA, Furuta T, Kojima S, et al. Antimalarial activity of extracts of Malaysian medicinal plants. J Ethnopharmacol. 1999;64:249-254.
31. Zhang CY, Tan BK. Mechanisms of cardiovascular activity of Andrographis paniculata in the anaesthetized rat. J Ethnopharmacol. 1997;56:97-101.
32. Kumar RA, Sridevi K, Kumar N V, et al. Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol. 2004;92:291-295.
33. Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188:564-570.
34. Sheeja K, Kuttan G. Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by Andrographis paniculata extract and andrographolide. Immunopharmacol Immunotoxicol. 2007;29:81-93.